MA26508A1 - Formulations pharmaceutiques contenant du variconazole, et procede pour leur preparation. - Google Patents

Formulations pharmaceutiques contenant du variconazole, et procede pour leur preparation.

Info

Publication number
MA26508A1
MA26508A1 MA25117A MA25117A MA26508A1 MA 26508 A1 MA26508 A1 MA 26508A1 MA 25117 A MA25117 A MA 25117A MA 25117 A MA25117 A MA 25117A MA 26508 A1 MA26508 A1 MA 26508A1
Authority
MA
Morocco
Prior art keywords
variconazole
preparation
pharmaceutical formulations
formulations containing
pharmaceutical
Prior art date
Application number
MA25117A
Other languages
English (en)
Inventor
Denise Harding Valerie
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10814734&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA26508(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of MA26508A1 publication Critical patent/MA26508A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
MA25117A 1997-06-21 1998-06-17 Formulations pharmaceutiques contenant du variconazole, et procede pour leur preparation. MA26508A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9713149.4A GB9713149D0 (en) 1997-06-21 1997-06-21 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
MA26508A1 true MA26508A1 (fr) 2004-12-20

Family

ID=10814734

Family Applications (1)

Application Number Title Priority Date Filing Date
MA25117A MA26508A1 (fr) 1997-06-21 1998-06-17 Formulations pharmaceutiques contenant du variconazole, et procede pour leur preparation.

Country Status (48)

Country Link
US (1) US6632803B1 (fr)
EP (1) EP1001813B8 (fr)
JP (2) JP2000513029A (fr)
KR (1) KR100372988B1 (fr)
CN (1) CN1125653C (fr)
AP (1) AP912A (fr)
AR (1) AR015900A1 (fr)
AT (1) ATE238812T1 (fr)
AU (1) AU724799B2 (fr)
BG (1) BG64584B1 (fr)
BR (1) BRPI9809468B8 (fr)
CA (1) CA2295035C (fr)
CO (1) CO4940450A1 (fr)
CZ (1) CZ289570B6 (fr)
DE (1) DE69814091T2 (fr)
DK (1) DK1001813T3 (fr)
DZ (1) DZ2523A1 (fr)
EA (1) EA001924B1 (fr)
EG (1) EG23910A (fr)
ES (1) ES2195355T3 (fr)
GB (1) GB9713149D0 (fr)
HK (1) HK1027966A1 (fr)
HR (1) HRP980341B1 (fr)
HU (1) HU228338B1 (fr)
ID (1) ID22939A (fr)
IL (1) IL132918A (fr)
IS (1) IS2004B (fr)
MA (1) MA26508A1 (fr)
ME (1) ME00907B (fr)
MY (1) MY118151A (fr)
NO (1) NO313125B1 (fr)
NZ (1) NZ501066A (fr)
OA (1) OA11232A (fr)
PA (1) PA8453201A1 (fr)
PE (1) PE84899A1 (fr)
PL (1) PL191295B1 (fr)
PT (1) PT1001813E (fr)
RS (1) RS49633B (fr)
SA (1) SA98190159B1 (fr)
SI (1) SI1001813T1 (fr)
SK (1) SK282946B6 (fr)
TN (1) TNSN98090A1 (fr)
TR (1) TR199903191T2 (fr)
TW (1) TW406023B (fr)
UA (1) UA57083C2 (fr)
UY (1) UY25055A1 (fr)
WO (1) WO1998058677A1 (fr)
ZA (1) ZA985364B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9818258D0 (en) * 1998-08-21 1998-10-14 Pfizer Ltd Antifungal compositions
PE20020300A1 (es) 2000-08-22 2002-05-10 Pharmacia Corp Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
AR031135A1 (es) 2000-10-10 2003-09-10 Upjohn Co Composiciones de antibiotico topico para el tratamiento de infecciones oculares
TWI307626B (en) * 2002-08-20 2009-03-21 Bristol Myers Squibb Co Aripiprazole complex formulation and method
GB0327390D0 (en) * 2003-11-25 2003-12-31 Pfizer Ltd Pharmaceutical formulations
WO2005055952A2 (fr) * 2003-12-08 2005-06-23 The Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions anticancereuses synergiques
WO2006004795A2 (fr) 2004-06-25 2006-01-12 The Johns Hopkins University Inhibiteurs d'angiogenese
US20100204178A1 (en) 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
WO2007047253A2 (fr) * 2005-10-11 2007-04-26 Eastman Chemical Company Formulations pharmaceutiques de cyclodextrines et composes antifongiques de type azole
AR061889A1 (es) 2006-07-13 2008-10-01 Medichem Sa Proceso mejorado para la preparacion de voriconazol
CN1919846B (zh) * 2006-09-14 2013-01-02 大道隆达（北京）医药科技发展有限公司 伏立康唑及其药用盐、中间体的一种新定向合成制备方法
BG1110U1 (bg) * 2007-06-19 2008-09-30 Рудолф ПОДЛИПСКИ Отоплителен съд за експресно локално загряване навода
EP2018866A1 (fr) * 2007-07-27 2009-01-28 Sandoz AG Compositions pharmaceutiques contenant du voriconazole
US8192721B2 (en) * 2007-12-13 2012-06-05 Verrow Pharmaceuticals, Inc. Compositions useful for reducing toxicity associated with gadolinium-based contrast agents
WO2009137611A2 (fr) * 2008-05-06 2009-11-12 Board Of Regents, The University Of Texas System Traitement d’infection fongique pulmonaire avec du voriconazole et par inhalation
EP2303265B1 (fr) * 2008-06-06 2014-12-10 Glenmark Pharmaceuticals Limited Formulation topique stable comprenant du voriconazole
CN101390825B (zh) * 2008-10-01 2010-12-29 山东省眼科研究所 一种伏立康唑眼内释药***
MX2011004225A (es) 2008-10-21 2011-06-21 Onyx Therapeutics Inc Terapia de combinacion con epoxicetonas peptidicas.
CN101444510B (zh) * 2008-12-31 2011-03-09 南京卡文迪许生物工程技术有限公司 含有伏立康唑的药物制剂及其制备方法
EP2467379B1 (fr) 2009-08-19 2016-03-02 ratiopharm GmbH Procédé pour la préparation des coévaporates et complexes comportant du voriconazole et cyclodextrine
WO2011064558A2 (fr) 2009-11-30 2011-06-03 Cipla Limited Composition pharmaceutique
CA2802929C (fr) 2010-06-29 2019-01-08 David Monteith Formulations d'une solution intraveineuse de posaconazole stabilisees par une cyclodextrine beta substituee
EP2409699B1 (fr) * 2010-07-23 2014-04-30 Combino Pharm, S.L. Compositions stables de voriconazole
CN102058519B (zh) * 2010-11-19 2013-01-02 苏州特瑞药业有限公司 一种伏立康唑缓释栓剂及其制备方法
EP2720723B1 (fr) 2011-06-15 2018-04-11 Synthon BV Composition de voriconazole stabilisée
EP2561863A1 (fr) 2011-08-22 2013-02-27 Farmaprojects, S.A.U. Compositions pharmaceutiques comportant du voriconazole
US20150030668A1 (en) * 2012-01-05 2015-01-29 Frederick Timothy Guilford Liposomally encapsulated reduced glutathione for management of cancer, including with other pharmaceutical compositions
US8853248B2 (en) 2012-04-05 2014-10-07 Hubert Maehr (1,2,3-triazolyl)sulfonyl derivatives
EP2662094B1 (fr) 2012-05-08 2024-04-17 Onyx Therapeutics, Inc. Procédés de complexation cyclodextrine pour formuler des inhibiteurs du protéasome de peptide
IN2014MN02236A (fr) 2012-05-11 2015-07-24 Cipla Ltd
BR112015016331B1 (pt) 2013-01-11 2020-05-12 Xellia Pharmaceuticals Aps Formulação farmacêutica estabilizada e método de estabilização de uma composição compreendendo voriconazol
CA2904670A1 (fr) 2013-03-14 2014-09-13 Fresenius Kabi Usa, Llc Formulations de voriconazole
GB201312737D0 (en) 2013-07-17 2013-08-28 Univ Greenwich Cyclodextrin
CN103690968A (zh) * 2013-11-21 2014-04-02 石药集团中奇制药技术（石家庄）有限公司 一种伏立康唑组合物及其制备方法
PT109117B (pt) * 2016-01-28 2019-02-01 Hovione Farm Sa Complexação de ingredientes ativos farmacêuticos
TW201828938A (zh) 2016-11-18 2018-08-16 德商艾庫里斯抗感染治療有限公司 以改質的環糊精及酸化劑為基底之經脒取代之β-內醯胺化合物的新穎調配物，其製備方法及作為抗微生物醫藥組合物之用途
US11040958B2 (en) 2017-02-17 2021-06-22 Wuhan Ll Science And Technology Development Co., Ltd. Triazole antimicrobial derivative, pharmaceutical composition and use thereof
CN113750034A (zh) * 2020-06-05 2021-12-07 中南大学湘雅三医院 耳用温敏凝胶及其制备方法
CN116570558B (zh) * 2023-06-21 2023-12-26 广州仁恒医药科技股份有限公司 一种伏立康唑眼用纳米缓释组合物及其制备方法和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346123A1 (de) 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
DE3347421A1 (de) 1983-12-29 1985-07-11 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von fluorarmen alkaliphosphatloesungen
GB8819308D0 (en) * 1988-08-13 1988-09-14 Pfizer Ltd Triazole antifungal agents
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9002375D0 (en) * 1990-02-02 1990-04-04 Pfizer Ltd Triazole antifungal agents
US5278175A (en) * 1990-02-02 1994-01-11 Pfizer Inc. Triazole antifungal agents
GB9512961D0 (en) * 1995-06-26 1995-08-30 Pfizer Ltd Antifungal agents
GB9602080D0 (en) 1996-02-02 1996-04-03 Pfizer Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
CZ409699A3 (cs) 2000-02-16
JP5089004B2 (ja) 2012-12-05
EA199900937A1 (ru) 2000-08-28
AU8110498A (en) 1999-01-04
PT1001813E (pt) 2003-07-31
HRP980341A2 (en) 1999-02-28
DK1001813T3 (da) 2003-07-28
PL191295B1 (pl) 2006-04-28
EG23910A (en) 2007-12-30
YU68199A (sh) 2002-06-19
CZ289570B6 (cs) 2002-02-13
AP912A (en) 2001-12-08
RS49633B (sr) 2007-08-03
UY25055A1 (es) 2000-12-29
NO995565L (no) 1999-11-30
US6632803B1 (en) 2003-10-14
HU228338B1 (en) 2013-03-28
GB9713149D0 (en) 1997-08-27
HUP0003323A2 (hu) 2001-06-28
AP9801268A0 (en) 1998-06-30
DZ2523A1 (fr) 2003-02-01
HUP0003323A3 (en) 2002-01-28
AR015900A1 (es) 2001-05-30
CA2295035A1 (fr) 1998-12-30
PE84899A1 (es) 1999-09-17
TW406023B (en) 2000-09-21
BRPI9809468B8 (pt) 2022-01-18
DE69814091T2 (de) 2004-01-22
KR100372988B1 (ko) 2003-02-25
PL337692A1 (en) 2000-08-28
CO4940450A1 (es) 2000-07-24
TNSN98090A1 (fr) 2005-03-15
TR199903191T2 (xx) 2000-09-21
ATE238812T1 (de) 2003-05-15
NZ501066A (en) 2001-01-26
MY118151A (en) 2004-09-30
PA8453201A1 (es) 2000-05-24
BG103882A (en) 2000-07-31
IS2004B (is) 2005-04-15
JP2002332234A (ja) 2002-11-22
BR9809468B1 (pt) 2013-11-12
OA11232A (en) 2003-05-26
UA57083C2 (uk) 2003-06-16
EA001924B1 (ru) 2001-10-22
IL132918A (en) 2001-09-13
IL132918A0 (en) 2001-03-19
EP1001813B8 (fr) 2014-02-12
NO995565D0 (no) 1999-11-12
BR9809468A (pt) 2000-06-20
HRP980341B1 (en) 2001-12-31
JP2000513029A (ja) 2000-10-03
ME00907B (me) 2007-08-03
SA98190159B1 (ar) 2005-12-21
CA2295035C (fr) 2005-04-19
WO1998058677A1 (fr) 1998-12-30
AU724799B2 (en) 2000-09-28
CN1261287A (zh) 2000-07-26
SI1001813T1 (en) 2004-02-29
ES2195355T3 (es) 2003-12-01
IS5248A (is) 1999-11-15
CN1125653C (zh) 2003-10-29
NO313125B1 (no) 2002-08-19
DE69814091D1 (de) 2003-06-05
EP1001813B1 (fr) 2003-05-02
ZA985364B (en) 1999-12-20
SK282946B6 (sk) 2003-01-09
KR20010014006A (ko) 2001-02-26
HK1027966A1 (en) 2001-02-02
BG64584B1 (bg) 2005-08-31
EP1001813A1 (fr) 2000-05-24
SK159399A3 (en) 2000-06-12
ID22939A (id) 1999-12-16

Similar Documents

Publication Publication Date Title
MA26508A1 (fr) Formulations pharmaceutiques contenant du variconazole, et procede pour leur preparation.
FR2780057B1 (fr) Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26472A1 (fr) Derives de n-hydroxy-b-sulfonylpropionamide, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26424A1 (fr) Derives de 6-phenylpyridyl-2-amine, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26687A1 (fr) 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26414A1 (fr) Derives de quinoleine et de quinazoline nouveaux, procede pour leur preparation et formulations pharmaceutiques les contenant.
MA26410A1 (fr) Formulations pharmaceutiques et procede pour leur production.
MA26499A1 (fr) Derives de tetrazole, procede pour leur preparation et compositions pharmaceutiques les contenant .
MA26471A1 (fr) Derives d'acide arylsulfonylaminohydroxamique, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26614A1 (fr) Bicyclo [2.2.1] heptanes nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26468A1 (fr) Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26622A1 (fr) Pyrazolopyrimidinones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26630A1 (fr) 4-phenylpyperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2729951B1 (fr) Nouveaux composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques en contenant
MA26558A1 (fr) Derives nouveaux de 6-0-methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26433A1 (fr) Derives de pyridylpyrrole, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26559A1 (fr) Derives de d-proline, procede pour leur preparation, compositions pharmaceutiques les contenant et leur utilisation
MA26516A1 (fr) Tartrate d'un dipeptide substitue, procede pour sa preparation et compositions pharmaceutiques le contenant.
MA26465A1 (fr) Derives de quinoleine et derives de quinazoline nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA26490A1 (fr) Derives de tetrahydroisoquinoleine nouveaux, procedes pour leur preparation et compositions pharmaceutiques les contenant.
MA26519A1 (fr) Derives d'azetidinylpropylpiperidine, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26707A1 (fr) Azalides nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26514A1 (fr) Agonistes de prostaglandines, procede pour leur preparation et compositions pharmaceutiques les contenant.
MA26567A1 (fr) Trifluoromethylethers cycliques a fonction piperidinylaminomethule, procede pour leur preparation et compositions pharmaceutiques les contenant
FR2751334B1 (fr) Polysaccharides synthetiques, procede pour leur preparation et compositions pharmaceutiques les contenant